• Binx Health

  Participated · Series D · Jan 2017

  Binx Health is a medical technology and diagnostic services provider. The company supplies testing, diagnostic and treatment services to clinics using its binx io testing instrument and a cartridge-based system. The binx io instrument and its cartridge are presented as the company’s core diagnostic products. According to the article, Binx Health recently completed a $65 million Series F financing. The reported financing round involved outside investors led by Hildred Capital with participation from EQT Life Sciences. binx health develops the binx io rapid molecular point-of-care testing platform, a CLIA‑waived solution that enables testing, diagnosis and treatment for chlamydia and gonorrhea during the same visit. The company supplies in‑clinic and at‑retail locations with its testing instrument and single‑use cartridges and is led by CEO Jeff Luber. It is expanding the platform into COVID‑19 testing by combining proprietary electrochemical detection with CRISPR methods. binx health plans to use recent funding to ramp manufacturing, scale its instrument and cartridges, expand sales in the U.S. and abroad, and further build out its proprietary software platform and data infrastructure. The company describes itself as a healthcare technology and diagnostics firm focused on rapid molecular point‑of‑care testing. Atlas Genetics is a Bath, England–based company that develops ultra-rapid point-of-care (POC) molecular diagnostic tests for infectious diseases. Its io® system is a molecular diagnostic platform built on a patent-protected electrochemical sensor technology. The system uses an integrated cartridge containing all reagents designed to accept an unprocessed clinical specimen; each cartridge can detect up to 24 different genetic targets. The company plans to use recent financing to support clinical trials and the commercial launch of a second test for detection of both Chlamydia and Gonorrhoea, targeting US regulatory approvals around the end of 2017. Atlas also intends to further develop its diagnostics menu and expand cartridge manufacturing capacity at Bespak. The company maintains a commercial office in Boston and is led by CEO Dr. John Clarkson. The firm reported closing a $35m Series D to fund these activities. Atlas Genetics develops the io(R) system, a novel point-of-care molecular diagnostic platform based on a patent‑protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs. The fully integrated cartridge contains all reagents, accepts an unprocessed clinical specimen and completes sample preparation, DNA amplification and electrochemical detection. Each cartridge can run up to 24 different tests from a single patient sample. The system is at an advanced stage of development and is expected to launch in Europe with a Chlamydia test later this year. The company plans to use the new funding to launch the io(R) system, initiate U.S. clinical trials and expand its test menu in STI and HAI markets. Atlas is led by CEO Dr John Clarkson. Atlas Genetics develops rapid decentralized and point-of-care (POC) molecular diagnostic tests for a range of infectious diseases, including sexually transmitted and hospital-acquired infections. Its Atlas io™ system is a patented electrochemical sensor–based molecular diagnostic platform that combines speed and accuracy while removing the need for costly optical components. The company is led by CEO Dr John Clarkson. Atlas intends to use the new funding to complete the transfer to manufacture of the Atlas io™ system and to file for European approval of its first Chlamydia test. The article reports a Series B financing, reflecting an active fundraising stage to support product commercialization and regulatory approval.

• Oxular

  Participated · Series A · Jul 2016

  Oxular develops sustained‑release formulations and a semi‑automated ocular delivery device to treat retinal diseases with the goal of providing up to 12 months of effect from a single administration. Its lead asset, OXU‑001, is a sustained‑release formulation of dexamethasone designed to provide up to 12 months of treatment for diabetic macular edema following one administration. The company’s platform includes Oxuspheres™, a biodegradable polymer sustained‑release system, and Oxulumis™, an illuminated microcatheter device for suprachoroidal delivery. Oxular says this combination aims to improve therapeutic precision, reduce treatment frequency, and lower the burden on patients and healthcare systems. Its pipeline includes OXU‑003 for retinoblastoma (recently granted Rare Pediatric Disease and Orphan‑Drug designations by the FDA), OXU‑004 for uveal melanoma, and OXU‑005 for AMD and diabetic retinopathy. The company plans Phase 2 studies for OXU‑001 and intends to advance OXU‑003 to Phase 2 in 2022, while preparing OXU‑004 and OXU‑005 for IND submissions; it raised financing to support these activities and to build its team. Precision Ocular is developing novel retinal treatments engineered to access specific small spaces in the eye and provide drug distribution to tissues involved in retinal diseases. Its product development pipeline targets prevalent retinal diseases such as age-related macular degeneration and diabetic macular oedema, as well as rare and orphan indications. The company also aims to enable development of next-generation ocular drug delivery systems capable of administering cell and gene therapies to the back of the eye. Founded in 2014 and led by CEO Tom Cavanagh, Precision Ocular is based in Oxford, UK. It closed a £15.5m Series A to advance these programs and platform technologies. Investors in the round include Imperial Innovations, Consort Medical plc, NeoMed, V-Bio Ventures and Hovione Scientia Ltd.

• Atlas

  Participated · Series B · Apr 2014

  Atlas develops ultra-rapid decentralized and point-of-care (POC) diagnostic tests for a range of infectious diseases built around its Atlas io system. The io system uses a patent-protected electrochemical sensor technology that removes the need for costly optical components and supports multiplex detection. The platform consists of an inexpensive Reader and a disposable cartridge and is designed to deliver accurate results within 30 minutes. Atlas completed the final tranche of a £16.9m Series B and the funds will be used to complete transfer to manufacture and to file for European approval of its first Chlamydia test. Clinical trials were scheduled for 2014 with a planned rollout in Europe and the United States pending regulatory approvals. The company, established in 2005, has head office and laboratory facilities near Bath and is targeting initial launches for Chlamydia and Gonorrhoea, conditions for which over 50 million tests are carried out annually in Europe and the US; the worldwide infectious-disease IVD market is cited at around US$9 billion.

No current team members are available.